Gilead's experimental HIV treatment shows low discontinuation rates in studies

2026-02-26 - 16:13

The company studied the pill in HIV patients whose virus was already suppressed, including those switching from complex multi-tablet regimens or from a guideline-recommended single-tablet treatment